Worth reading
49Recurring
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Receipt of a preliminary, non-binding joint proposal concerning taking the Company's shares private
Subject Entity
KOBAYASHI PHARMACEUTICAL CO.,LTD. (proposers: Nippon Sangyo Suishin Kiko (NSSK) and an affiliated entity of CVC Capital Partners)
Target Locations / Products
Shares of KOBAYASHI PHARMACEUTICAL CO.,LTD. (going-private transaction)
This disclosure09/25/2026
Cause
One option for enhancing corporate value
Outlook
If it decides that a fact requiring disclosure has arisen, it will announce it promptly
| Item | Details |
|---|---|
| Event name | Receipt of a preliminary, non-binding joint proposal concerning taking the Company's shares private |
| Subject Entity | KOBAYASHI PHARMACEUTICAL CO.,LTD. (proposers: Nippon Sangyo Suishin Kiko (NSSK) and an affiliated entity of CVC Capital Partners) |
| Target Locations / Products | Shares of KOBAYASHI PHARMACEUTICAL CO.,LTD. (going-private transaction) |
| Cause | One option for enhancing corporate value |
| Outlook | If it decides that a fact requiring disclosure has arisen, it will announce it promptly |
| Planned follow-up disclosure | If it decides that a fact requiring disclosure has arisen, it will announce it promptly |
Items this document does not state (19)
Date of occurrenceDate recognized / date notice receivedAmount of Impact on Business PerformanceAccounting period in which recognizedImpact on Earnings ForecastType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the change
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company stated that it had received the proposal as one option for enhancing corporate value.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.